A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL

Venetoclax (VEN) is approved for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as monotherapy (VENmono) or in combination with rituximab. Whether VEN plus anti-CD20 (VENcombo) is superior to VENmono is unknown. We conducted a multicenter, retrospective cohort analysis comparing 321 CL...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Blood Adv
Κύριοι συγγραφείς: Mato, Anthony R., Roeker, Lindsey E., Eyre, Toby A., Nabhan, Chadi, Lamanna, Nicole, Hill, Brian T., Brander, Danielle M., Barr, Paul M., Lansigan, Frederick, Cheson, Bruce D., Singavi, Arun K., Yazdy, Maryam Sarraf, Shah, Nirav N., Allan, John N., Bhavsar, Erica B., Rhodes, Joanna, Kennard, Kaitlin, Schuster, Stephen J., Williams, AnnaLynn M., Skarbnik, Alan P., Goy, Andre H., Goodfriend, Julie M., Dorsey, Colleen, Coombs, Catherine C., Tuncer, Hande, Ujjani, Chaitra S., Jacobs, Ryan, Winter, Allison M., Pagel, John M., Bailey, Neil, Schuh, Anna, Shadman, Mazyar, Sitlinger, Andrea, Weissbrot, Hanna, Muralikrishnan, Sivraj, Zelenetz, Andrew, Kirkwood, Amy A., Fox, Christopher P.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Hematology 2019
Θέματα:
Lymphoid Neoplasia
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6538868/
https://ncbi.nlm.nih.gov/pubmed/31101647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000180
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια